Medication info
Orotenion Tablet 5/20 mg (Amlodipine Besilate, Olmesartan Medoxomil)

Orotenion Tablet 5/20 mg (Amlodipine Besilate, Olmesartan Medoxomil)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Korea Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
28 tablets (14 tablets/PTP × 2)
Approval status
Active

MFDS item code 201505939 · Approved 2015.08.25 · Insurance code 642802790

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet of this medicine once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil); however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using either individual component. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. · Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal failure (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. · Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. · Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this medicine to patients with severe hepatic impairment (see Precautions for Use, 2. Do not administer to the following patients). · Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, monitor blood pressure closely and more frequently.
Child dose
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.

Ingredients

Manufacturer
Korea Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medicine is used to effectively control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled with either amlodipine or olmesartan medoxomil monotherapy.

How to take

Adult dose

Administer 1 tablet of this medicine once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil); however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using either individual component. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. · Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal failure (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. · Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. · Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this medicine to patients with severe hepatic impairment (see Precautions for Use, 2. Do not administer to the following patients). · Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, monitor blood pressure closely and more frequently.

Child dose

The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus, especially during the 2nd and 3rd trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Those allergic to this medication or similar drugs, individuals who are pregnant or breastfeeding, people with severe liver or heart diseases, patients undergoing renal dialysis, those in shock, and patients with certain types of diabetes should not take this medication. Hypertensive patients who are deficient in fluids or sodium may experience excessively low blood pressure at the start of treatment, so they must be monitored carefully, and appropriate measures should be taken immediately if symptoms appear. Because rapid vasodilation can lead to hypotension, individuals with problems related to the heart or blood vessels should be particularly cautious. Patients with impaired kidney function may experience changes in renal function while taking this medication, so regular examinations are necessary. Patients with decreased liver function may experience delayed metabolism of this medication, so caution is advised during administration. Various side effects such as dizziness, headache, nausea, and edema can occur while taking this medication, and if symptoms worsen, consultation with a healthcare professional is recommended. Elderly patients may be more sensitive to this medication, so dosage adjustments and close monitoring of their condition are necessary. When taking this medication with other drugs, interactions may occur, so all medications currently being taken must be reported to the healthcare professional. Taking this medication during pregnancy may cause renal damage or other serious problems in the fetus, so individuals who are planning to become pregnant or who are pregnant must consult a doctor. In breastfeeding women, this medication may pass into breast milk and affect the baby, so it is recommended to discontinue breastfeeding or to stop taking this medication. Safety and efficacy for children under 18 years have not been established, therefore its use is not recommended. Overdosing on this medication can lead to severe hypotension and cardiac issues, so dosage should be adhered to strictly, and immediate medical attention should be sought in case of overdose. This medication should be kept out of reach of children and stored in a cool, dry place away from direct sunlight and moisture.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory loss
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • swelling
  • pitting edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • double vision
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • urticaria
  • autoimmune hepatitis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture, and should be kept at room temperature between 1 and 30 degrees Celsius. This way, the effectiveness of the medication can be well maintained.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

28 tablets (14 tablets/PTP × 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.